(lp0
S"Nektar Therapeutics' stock jumps after positive results of its pain treatment drug MarketWatch - Mar 20, 2017 Shares of Nektar Therapeutics NKTR, +2.80% soared 18% toward a six-month high in premarket trade Monday, after reporting positive results of a late-stage trial of its opioid analgesic.Why Nektar Therapeutics Inc. Is Rising Today - Motley FoolNektar Therapeutics 's Opioid-Based Drug Performs Well In Phase 3 ... - Journal Transcript"
p1
aS'Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology ... PR Newswire  - Apr 4, 2017 SAN FRANCISCO, April 4, 2017 /PRNewswire/ -- Nektar Therapeutics  today announced five preclinical data presentations for its immuno-oncology programs made at the American Association for Cancer Research  Annual Meeting&nbsp;...Nektar Therapeutics  Up 57.2% Since Earnings Report: Can It Continue? - Yahoo FinanceNektar Therapeutics  PT Raised to $27 at Aegis Capital on Market ... - StreetInsider.com'
p2
aS"Could Nektar Therapeutics Be Worth More? Motley Fool - Mar 23, 2017 Nektar Therapeutics  is an intriguing commercial-stage biotech company that's just reported positive late-stage trial results for its pain-busting drug NKTR-181.Stock for Your Case: Nektar Therapeutics  - StandardOracleMost Active Volume Stock: Nektar Therapeutics  - HugoPress"
p3
aS'Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out Forbes - Mar 30, 2017 These four stocks, two of them biotechs and two technology, have strong technical momentum. Cara Therapeutics Inc.  had a nice follow-through on Tuesday, jumping 94 cents, or 5%, to $19.09, on 7.6 million shares.'
p4
aS'Piper Jaffray Reiterates Overweight Rating and $29 PT on Nektar Therapeutics ... StreetInsider.com - Apr 10, 2017 Piper Jaffray reiterates Overweight rating and $29 price target on Nektar Therapeutics  following meetings with management.'
p5
aS"Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and ... Yahoo Finance - Apr 10, 2017 NEW YORK, NY / ACCESSWIRE / April 10, 2017 / The iShares NASDAQ Biotechnology Index ETF gained 0.80 percent to close at 290.52, up 9.47 percent year-to-date.Nektar Therapeutics  Plunges 8.01% on April 10 - Equities.comHot Stock to Watch: Nektar Therapeutics  - HugoPress"
p6
aS'The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex ... Yahoo Finance - Apr 7, 2017 Stocks recently featured in the blog include Esperion Therapeutics, Inc. , Vertex Pharmaceuticals Incorporated , Nektar Therapeutics , Argos Therapeutics, Inc.'
p7
aS'BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in ... Reuters - Mar 20, 2017 BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in Phase 3 summit-07 study in chronic pain. March 20 Nektar Therapeutics. * Nektar Therapeutics says NKTR-181, an opioid analgesic, meets primary and secondary endpoints&nbsp;...'
p8
aS"Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class ... PR Newswire  - Mar 27, 2017 SAN FRANCISCO, March 27, 2017 /PRNewswire/ -- Nektar Therapeutics  today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new biologic therapy, which is being developed to treat a&nbsp;..."
p9
aS"BRIEF-Nektar Therapeutics presents new preclinical data for its immuno ... Reuters - Apr 4, 2017 NEW YORK, April 4 More companies, including carmaker BMW and insurer Allstate, have pulled their advertising from Fox News' &quot;The O'Reilly Factor&quot; television program days after the New York Times reported Fox and star host Bill O'Reilly paid five women&nbsp;..."
p10
a.